469 related articles for article (PubMed ID: 30692991)
1. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.
Dar TB; Henson RM; Shiao SL
Front Immunol; 2018; 9():3077. PubMed ID: 30692991
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
Yang Y; Li L; Jiang Z; Wang B; Pan Z
Cancer Immunol Immunother; 2020 Dec; 69(12):2523-2532. PubMed ID: 32577817
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity.
Brandmaier A; Formenti SC
Semin Radiat Oncol; 2020 Apr; 30(2):139-144. PubMed ID: 32381293
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
5. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
[TBL] [Abstract][Full Text] [Related]
6. Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.
Karan D
Front Immunol; 2018; 9():3028. PubMed ID: 30631327
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
8. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
9. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
10. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
11. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum RR; Liang H; Deng L; Fu YX
Nat Rev Clin Oncol; 2017 Jun; 14(6):365-379. PubMed ID: 28094262
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
14. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
15. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
[TBL] [Abstract][Full Text] [Related]
16. Immune biological rationales for the design of combined radio- and immunotherapies.
Hader M; Frey B; Fietkau R; Hecht M; Gaipl US
Cancer Immunol Immunother; 2020 Feb; 69(2):293-306. PubMed ID: 31953578
[TBL] [Abstract][Full Text] [Related]
17. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.
Roses RE; Datta J; Czerniecki BJ
Radiat Res; 2014 Aug; 182(2):211-8. PubMed ID: 24992163
[TBL] [Abstract][Full Text] [Related]
18. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
19. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
20. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]